Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells.

Oncotarget - 21 Jun 2016

Jochems Caroline, Fantini Massimo, Fernando Romaine I, Kwilas Anna R, Donahue Renee N, Lepone Lauren M, Grenga Italia, Kim Young-Seung, Brechbiel Martin W, Gulley James L, Madan Ravi A, Heery Christopher R, Hodge James W, Newton Robert, Schlom Jeffrey, Tsang Kwong Y

Abstract excerpt

Epacadostat is a novel inhibitor of indoleamine-2,3-dioxygenase-1 (IDO1) that suppresses systemic tryptophan catabolism and is currently being evaluated in ongoing clinical trials. We investigated the effects of epacadostat on (a) human dendritic cells (DCs) with respect to maturation and ability to activate human tumor antigen-specific cytotoxic T-cell (CTL) lines, and subsequent T-cell lysis of tumor cells, (b)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Vaccines
Share to Granulocyte-Macrophage Colony-Stimulating Factor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Healthy Volunteers

Share to Indoleamine-Pyrrole 2,3,-Dioxygenase

Share to Kynurenine

Share to Oximes

Share to T-Lymphocytes, Cytotoxic

Share to Tryptophan

Source

Open in PubMed Open full text

Identifiers

PMID: 27192116
DOI: 10.18632/oncotarget.9326
PMCID: PMC5122347

Genes

IDO1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells.PMID 27192116Read ↗

Human type 1 and type 2 conventional dendritic cells express indoleamine 2,3-dioxygenase 1 with functional effects on T cell priming.Semantic proximity Read ↗

Indoleamine 2,3-Dioxygenase and Dendritic Cell TolerogenicitySemantic proximity Read ↗

Tumoricidal activity of human dendritic cells.Semantic proximity Read ↗

RAD001-mediated mTOR targeting in human monocyte-derived dendritic cells shifts them toward an immunogenic phenotype.Semantic proximity Read ↗

Natural CD4+ T-Cell Responses against Indoleamine 2,3-DioxygenaseSemantic proximity Read ↗

Hiltonol and Protamine-RNA stimulation induce an immune-activating transcriptome profile in cDC1sSemantic proximity Read ↗

What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the pastSemantic proximity Read ↗

Current Challenges for IDO2 as Target in Cancer ImmunotherapySemantic proximity Read ↗

Activation of the Regulatory T-Cell/Indoleamine 2,3-Dioxygenase Axis Reduces Vascular Inflammation and Atherosclerosis in Hyperlipidemic Mice.Semantic proximity Read ↗

Identification of IDO-positive and IDO-negative human dendritic cells after activation by various proinflammatory stimuli.Semantic proximity Read ↗

The CSF-1R inhibitor Pexidartinib impacts dendritic cell differentiation through inhibition of FLT3 signaling and may antagonize the effect of durvalumab in patients with advanced cancer – results from a phase 1 studySemantic proximity Read ↗

Peptide vaccination directed against IDO1-expressing immune cells elicits CD8+ and CD4+ T-cell-mediated antitumor immunity and enhanced anti-PD1 responsesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.